Inhalation

Nebulizers

Kenox boasts extensive expertise in nebulizer technology, encompassing established (jet, ultrasound) and cutting-edge (vibrating mesh) platforms. We stay abreast of their latest advancements, including breath-actuation and -enhancement features, through our strong partnerships with leading suppliers and innovators. Our successful track record encompasses numerous pre-clinical development programs for diverse molecules like low/high-dose repurposed molecules, new chemical entities (NCEs), and peptides. Our formulation expertise spans both solution and suspension-based formulations, ensuring optimal drug delivery tailored to the unique requirements of the program.

Soft Mist Inhalers (SMIs)

Kenox spearheads the advancement of SMI technology, unlocking its potential for delivering both small molecules and biologics to the lungs. We are one of the very few companies possessing in-depth knowledge and proven know-how of SMI development, which is showcased by our strategic partnership with Boehringer Ingelheim. Kenox is the preferred pre-clinical development partner for Respimat® technology.

Dry Powder Inhalers (DPIs)

Kenox boasts a proven track record in end-to-end development and manufacturing of marketed DPI products across different platforms (capsule, reservoir or blister). Our expertise spans both carrier-based and drug-only formulations, allowing us to tailor solutions to each molecule's unique needs. We understand the critical interplay between raw material attributes, process parameters, and device characteristics – essential for successful DPI development. Leveraging this deep understanding and years of hands-on experience, we propel our partner and customer programs from molecule to first-in-human studies with efficiency and success.

Metered Dose Inhalers (MDIs)

Kenox is at the forefront of developing sustainable inhalation products by focusing on feasibility studies transitioning from Hydrofluoroalkanes (HFAs) to greener propellants. We are equipped to handle and utilize low Global Warming Potential (GWP) propellants, including HFA-152a and HFO-1234ze, at R&D scale. Our expert services in this area encompass:

Reverse engineering of existing HFA-based products to understand their formulation and functionality
Early-stage solubility and compatibility trials using crimped glass vials for efficient and reliable data generation
Design of Experiments to optimize new propellant for your specific inhalation product